Clinical and Cost Considerations for Value-Based Multiple Sclerosis Care

Clinical and Cost Considerations for Value-Based Multiple Sclerosis Care

On-Demand Webcast

H. Eric Cannon, PharmD, FAMCP
Vice President of Pharmacy Benefits 
Murray, Utah

Clyde E. Markowitz, MD
Director, Multiple Sclerosis Center
Associate Professor of Neurology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Intended Learners

This activity is designed for pharmacy directors, medical directors, and other decision makers working in managed care organizations.

Learning Objectives

After completing this activity, participants should be able to:

  • Recognize the downstream clinical and economic consequences of delayed or suboptimal MS treatment
  • Distinguish among available and emerging DMTs for MS in terms of their mechanisms of action, efficacy, safety, and administration
  • Outline key considerations for starting, changing, and stopping DMT in patients with MS
  • Integrate the risks, benefits, and current recommended therapeutic placement of MS therapies into informed health plan decisions that facilitate optimal treatment access and adherence
Activity Overview

In order to be eligible for documentation of credit, participants must complete the pre-test, attend the full webinar, complete the 10-question post-test with a score of 75% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at, where participants may immediately print their documentation of credit. Participants will be asked to complete a pre-activity survey, post-activity survey and evaluation following the educational session. Participants will be asked to log in or create an account at

Release Date: January 15, 2019
Expiration Date: January 15, 2020
Estimated Time to Complete: 1 hour

There is no fee associated with this activity.

For questions regarding this educational activity, please call 609-371-1137.

Hardware/Software Requirements

All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested (please download here) for video programs. A PDF reader is required for print publications. Please direct technical questions to



In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and HorizonCME. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



NACCME designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This continuing nursing education activity awards 1 contact hour.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1 contact hour.


This activity is approved for 1.0 contact hour (.10 CEU) of continuing pharmacy education (UAN JA0006201-9999-19-007-H01-P).

This educational activity is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, Suite 200, East Windsor, NJ 08520. The Senior Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

ACPE Credit Policy

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. The reporting function into CPE Monitor will only be available for 60 days after your completion of the activity.  Under ACPE Policy, NACCME will not be able to report your credit to CPE Monitor after this 60 day period.

Planning Committee

The planning committee is comprised of Clyde E. Markowitz, MD; H. Eric Cannon, PharmD, FAMCP; Susie Seaman, NP;  Brian Lee, PharmD and Katie Oakes, HorizonCME; and Donna Brophy, Jennifer Browne, Molly Duda, Jennifer Ilcyn, Michael Kearney, Randy Robbin, Susan Yarbrough, NACCME

Independent Clinical Reviewer: Bernard Abrams, MD, Clinical Professor of Neurology, University of Missouri-Kansas City, Kansas City, Missouri

Nurse Planner: Susie Seaman, NP, Sharp Rees-Stealy Wound Clinic, San Diego, California

Financial Disclosures and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. CannonConsultantLilly, Sanofi; EmployeeSelectHealth

Dr. Markowitz: Consultant—Bayer, Biogen, Genentech/Roche, Merck-Serono, Novartis, Sanofi/Genzyme, and Teva/Mylan.

Ms. Seaman: Advisory Board – MoInlycke Health Care

Dr. Abrams has disclosed no relevant financial relationships with any commercial interest.

Ms. Brophy, Ms. Browne, Ms. Duda, Ms. Ilcyn, Mr. Kearney, Dr. Lee, Ms. Oakes, Mr. Robbin, Ms. Yarbrough have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty has disclosed no off label/unapproved uses of drugs and/or devices will be discussed in the presentations.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering

Provided by North American Center for Continuing Medical Education, LLC, An HMP Company.

Grant Support

Supported by educational grants from Biogen and Sanofi Genzyme.